-DOCSTART- -X- O
Background. -X- _ O
Annual -X- _ O
influenza -X- _ O
epidemics -X- _ O
are -X- _ O
responsible -X- _ O
for -X- _ O
substantial -X- _ O
morbidity -X- _ O
and -X- _ O
mortality. -X- _ O
The -X- _ O
use -X- _ O
of -X- _ O
immunomodulatory -X- _ O
agents -X- _ O
such -X- _ O
as -X- _ O
statins -X- _ O
to -X- _ O
target -X- _ O
host -X- _ O
inflammatory -X- _ O
responses -X- _ O
in -X- _ O
influenza -X- _ O
virus -X- _ O
infection -X- _ O
has -X- _ O
been -X- _ O
suggested -X- _ O
as -X- _ O
an -X- _ O
adjunct -X- _ O
treatment -X- _ O
, -X- _ O
especially -X- _ O
during -X- _ O
pandemics -X- _ O
, -X- _ O
when -X- _ O
antiviral -X- _ O
quantities -X- _ O
are -X- _ O
limited -X- _ O
or -X- _ O
vaccine -X- _ O
production -X- _ O
can -X- _ O
be -X- _ O
delayed. -X- _ O
Methods. -X- _ O
We -X- _ O
used -X- _ O
population-based -X- _ O
, -X- _ O
influenza -X- _ O
hospitalization -X- _ O
surveillance -X- _ O
data -X- _ O
, -X- _ O
propensity -X- _ O
score-matched -X- _ O
analysis -X- _ O
, -X- _ O
and -X- _ O
Cox -X- _ O
regression -X- _ O
to -X- _ O
determine -X- _ O
whether -X- _ O
there -X- _ O
was -X- _ O
an -X- _ O
association -X- _ O
between -X- _ O
mortality -X- _ O
( -X- _ O
within -X- _ O
30 -X- _ O
days -X- _ O
of -X- _ O
a -X- _ O
positive -X- _ O
influenza -X- _ O
test -X- _ O
) -X- _ O
and -X- _ O
statin -X- _ B-Intervention
treatment -X- _ I-Intervention
among -X- _ O
hospitalized -X- _ B-Patient
cohorts -X- _ I-Patient
from -X- _ I-Patient
2 -X- _ I-Patient
influenza -X- _ I-Patient
seasons -X- _ I-Patient
( -X- _ I-Patient
October -X- _ I-Patient
1 -X- _ I-Patient
, -X- _ I-Patient
2007 -X- _ I-Patient
to -X- _ I-Patient
April -X- _ I-Patient
30 -X- _ I-Patient
, -X- _ I-Patient
2008 -X- _ I-Patient
and -X- _ I-Patient
September -X- _ I-Patient
1 -X- _ I-Patient
, -X- _ I-Patient
2009 -X- _ I-Patient
to -X- _ I-Patient
April -X- _ I-Patient
31 -X- _ I-Patient
, -X- _ I-Patient
2010 -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
Results. -X- _ O
Hazard -X- _ O
ratios -X- _ O
for -X- _ O
death -X- _ O
within -X- _ O
the -X- _ O
30-day -X- _ O
follow-up -X- _ O
period -X- _ O
were -X- _ O
0.41 -X- _ O
( -X- _ O
95 -X- _ O
% -X- _ O
confidence -X- _ O
interval -X- _ O
[ -X- _ O
CI -X- _ O
] -X- _ O
, -X- _ O
.25–.68 -X- _ O
) -X- _ O
for -X- _ O
a -X- _ O
matched -X- _ O
sample -X- _ O
from -X- _ O
the -X- _ O
2007–2008 -X- _ O
season -X- _ O
and -X- _ O
0.77 -X- _ O
( -X- _ O
95 -X- _ O
% -X- _ O
CI -X- _ O
, -X- _ O
.43–1.36 -X- _ O
) -X- _ O
for -X- _ O
a -X- _ O
matched -X- _ O
sample -X- _ O
from -X- _ O
the -X- _ O
2009 -X- _ O
pandemic. -X- _ O
Conclusions. -X- _ O
The -X- _ O
analysis -X- _ O
suggests -X- _ O
a -X- _ O
protective -X- _ B-Outcome
effect -X- _ I-Outcome
against -X- _ I-Outcome
death -X- _ I-Outcome
from -X- _ I-Outcome
influenza -X- _ I-Outcome
among -X- _ I-Outcome
patients -X- _ I-Outcome
hospitalized -X- _ I-Outcome
in -X- _ I-Outcome
2007–2008 -X- _ I-Outcome
but -X- _ I-Outcome
not -X- _ I-Outcome
during -X- _ I-Outcome
the -X- _ I-Outcome
pandemic. -X- _ I-Outcome
Sensitivity -X- _ I-Outcome
analysis -X- _ I-Outcome
indicates -X- _ I-Outcome
the -X- _ I-Outcome
findings -X- _ I-Outcome
for -X- _ I-Outcome
2007–2008 -X- _ I-Outcome
may -X- _ I-Outcome
be -X- _ I-Outcome
influenced -X- _ I-Outcome
by -X- _ I-Outcome
unmeasured -X- _ I-Outcome
confounders. -X- _ I-Outcome
This -X- _ I-Outcome
analysis -X- _ I-Outcome
does -X- _ I-Outcome
not -X- _ I-Outcome
support -X- _ I-Outcome
using -X- _ I-Outcome
statins -X- _ I-Outcome
as -X- _ I-Outcome
an -X- _ I-Outcome
adjunct -X- _ I-Outcome
treatment -X- _ I-Outcome
for -X- _ I-Outcome
preventing -X- _ I-Outcome
death -X- _ I-Outcome
among -X- _ I-Outcome
persons -X- _ I-Outcome
hospitalized -X- _ I-Outcome
for -X- _ I-Outcome
influenza -X- _ I-Outcome
. -X- _ O

